Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)
出版年份 2022 全文链接
标题
Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2022-07-23
DOI
10.1200/jco.22.00229
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial
- (2021) Laura D. Locati et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
- (2020) R. Kurzrock et al. ANNALS OF ONCOLOGY
- ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
- (2019) Laura Cato et al. CANCER CELL
- Biomarker Immunoprofile and molecular characteristics in salivary duct carcinoma: Clinicopathologic and prognostic implications
- (2019) Thalita Santana et al. HUMAN PATHOLOGY
- Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
- (2019) Wim Boxtel et al. INTERNATIONAL JOURNAL OF CANCER
- A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands
- (2018) Eline Boon et al. INTERNATIONAL JOURNAL OF CANCER
- Expression pattern of androgen receptor and AR-V7 in androgen deprivation therapy naïve salivary duct carcinomas
- (2018) Richard K. Yang et al. HUMAN PATHOLOGY
- Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma
- (2018) Hideaki Takahashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands
- (2017) Eline Boon et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Somatic mutations in salivary duct carcinoma and potential therapeutic targets
- (2017) Timothy K. Khoo et al. Oncotarget
- Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification
- (2017) Soichiro Takase et al. Oncotarget
- Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
- (2016) K. Wang et al. CLINICAL CANCER RESEARCH
- Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
- (2016) M. G. Dalin et al. CLINICAL CANCER RESEARCH
- Molecular Characterization of Apocrine Salivary Duct Carcinoma
- (2015) Simion I. Chiosea et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Salivary Duct Carcinoma
- (2015) Lindsay Williams et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells
- (2015) Sakthivel Muniyan et al. CELLULAR SIGNALLING
- Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results
- (2015) Bertrand Tombal et al. EUROPEAN UROLOGY
- Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations
- (2015) Peter P. Luk et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
- (2015) Masaki Shiota et al. Oncotarget
- Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications
- (2014) Y. Mitani et al. CLINICAL CANCER RESEARCH
- Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma
- (2014) Tatsuo Masubuchi et al. International Journal of Clinical Oncology
- Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
- (2014) Bertrand Tombal et al. LANCET ONCOLOGY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment
- (2012) V. Nardi et al. CLINICAL CANCER RESEARCH
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor–Positive Salivary Duct Carcinoma: A Disease Entity With Promising New Treatment Options
- (2011) Heidy C.J. Jaspers et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)
- (2009) Laura D. Locati et al. ORAL ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started